Loading
A phase 2 trial of capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin), bevacizumab (glioblastoma use) and tislelizumab in colorectal cancer, run by Shanghai Changzheng Hospital, now recruiting.
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer is a phase 2, interventional study registered as NCT06881537 by Shanghai Changzheng Hospital, with a registry enrolment figure of 15 participants, started 2024-06-01 and due to reach its primary completion in 2025-06-30. Interventions recorded: Capecitabine; Oxaliplatin; Bevacizumab; Tislelizumab. Conditions listed: Locally Recurrent Colorectal Cancer. Primary outcome: Objective response rate; R0 resection rate; Pathological complete response rate. Colorectal eligibility wording from the registry: "* Primary colorectal cancer underwent radical surgery, histologically confirmed as adenocarcinoma and achieved R0 resection, and postoperative adjuvant chemotherapy with Xelox or other first-line standard regimens". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/